Sewgobind Varsha D K D, van der Laan Luc J W, Klepper Mariska, Ijzermans Jan N M, Tilanus Huug W, Weimar Willem, Baan Carla C
Departments of Internal Medicine and Surgery Erasmus MC, University medical Center, Rotterdam, The Netherlands.
Clin Transplant. 2008 Sep-Oct;22(5):579-86. doi: 10.1111/j.1399-0012.2008.00827.x. Epub 2008 Apr 23.
The role of CD4(+) CD25(bright) regulatory T cells (Treg) in controlling alloreactivity is established, but little is known whether antigen-specific Treg are induced in fully immunosuppressed kidney transplant patients.
The frequency and function of CD25(bright) T cells of nine stable kidney transplant patients before and 0.5-2 yr after transplantation were measured. Patients received triple therapy consisting of cyclosporine, mycophenolate mofetil and prednisone. To investigate the influence of transplantation and immunosuppression on Treg function, we compared their suppressive capacities pre- and post-transplantation using mixed lymphocyte reactions and kept the CD25(-/dim) effector T-cell (Teff) population constant.
After transplantation, the percentage of CD4(+) CD25(bright) T cells significantly decreased from 8.5% pre-transplant to 6.9% post-transplant (median, p = 0.05). However, the lower percentage of post-transplant CD4(+) CD25(bright) T cells was not associated with reduced, but rather improved suppressor function of these cells. The proliferative response of pre-transplant Teff to donor-antigens was more profoundly suppressed by post-transplant Treg than by pre-transplant Treg (pre-transplant 18% vs. post-transplant 55% median, p = 0.03) and was comparable against third party antigens at a CD25(bright):CD25(-/dim) ratio of 1:20.
In immunosuppressed kidney transplant patients, the donor-directed suppressive capacity of CD4(+) CD25(bright) regulatory T cells improved, which may contribute to the development of donor-specific hyporesponsiveness against the graft.
CD4(+) CD25(bright) 调节性T细胞(Treg)在控制同种异体反应性中的作用已得到确立,但对于在完全免疫抑制的肾移植患者中是否诱导产生抗原特异性Treg却知之甚少。
测定了9例稳定肾移植患者移植前及移植后0.5 - 2年CD25(bright) T细胞的频率和功能。患者接受环孢素、霉酚酸酯和泼尼松组成的三联疗法。为研究移植和免疫抑制对Treg功能的影响,我们通过混合淋巴细胞反应比较了移植前后它们的抑制能力,并使CD25(-/dim)效应T细胞(Teff)群体保持恒定。
移植后,CD4(+) CD25(bright) T细胞百分比从移植前的8.5%显著降至移植后的6.9%(中位数,p = 0.05)。然而,移植后CD4(+) CD25(bright) T细胞百分比降低与这些细胞抑制功能的降低无关,反而与功能改善有关。移植后Treg对移植前Teff对供体抗原的增殖反应的抑制作用比移植前Treg更显著(移植前中位数为18%,移植后为55%,p = 0.03),并且在CD25(bright):CD25(-/dim) 比例为1:20时,对第三方抗原的抑制作用相当。
在免疫抑制的肾移植患者中,CD4(+) CD25(bright) 调节性T细胞的供体定向抑制能力得到改善,这可能有助于形成针对移植物的供体特异性低反应性。